Seoyoung Catherine Kim, Sc.D., M.D.
This page shows the publications co-authored by Seoyoung Kim and Joseph Merola.
Patient characteristics associated with use of TNF vs interleukin inhibitors as first-line biologic treatment for psoriatic arthritis. J Manag Care Spec Pharm. 2021 Aug; 27(8):1106-1117.
Risk of Hospitalized Serious Infection After Initiating Ustekinumab or Other Biologics for Psoriasis or Psoriatic Arthritis. Arthritis Care Res (Hoboken). 2021 May 10.
Validation of claims-based algorithms to identify patients with psoriasis. Pharmacoepidemiol Drug Saf. 2021 07; 30(7):868-874.
Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. J Am Acad Dermatol. 2021 Feb; 84(2):300-311.
Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa. JAMA Dermatol. 2020 03 01; 156(3):342-345.
Patterns of Systemic Treatment for Psoriatic Arthritis in the US: 2004-2015. Arthritis Care Res (Hoboken). 2018 05; 70(5):791-796.
Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. JAMA Dermatol. 2021 07 01; 157(7):805-816.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.